[PDF][PDF] Dysphagia in head and neck cancer patients: pretreatment evaluation, predictive factors, and assessment during radio-chemotherapy, recommendations
N Denaro, MC Merlano… - Clinical and experimental …, 2013 - synapse.koreamed.org
Progress in head and neck cancer (HNC) therapies has improved tumor response, loco-
regional control, and survival. However, treatment intensification also increases early and …
regional control, and survival. However, treatment intensification also increases early and …
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open …
JB Vermorken, J Stöhlmacher-Williams… - The lancet …, 2013 - thelancet.com
Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve
clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma of the …
clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma of the …
[HTML][HTML] Critical weight loss is a major prognostic indicator for disease-specific survival in patients with head and neck cancer receiving radiotherapy
JAE Langius, S Bakker, DHF Rietveld… - British journal of …, 2013 - nature.com
Background: Pre-treatment weight loss (WL) is a prognostic indicator for overall survival
(OS) in head and neck cancer (HNC) patients. This study investigates the association …
(OS) in head and neck cancer (HNC) patients. This study investigates the association …
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology …
A Argiris, M Ghebremichael, J Gilbert… - Journal of Clinical …, 2013 - ascopubs.org
Purpose We hypothesized that the addition of gefitinib, an epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor, to docetaxel would enhance therapeutic efficacy in …
(EGFR) tyrosine kinase inhibitor, to docetaxel would enhance therapeutic efficacy in …
Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management …
F Peyrade, D Cupissol, L Geoffrois, F Rolland, C Borel… - Oral oncology, 2013 - Elsevier
OBJECTIVE: Worldwide, head and neck carcinomas account for 5% of all malignancies.
Two-thirds of patients relapse after initial multimodal therapy. Until early 2000, the median …
Two-thirds of patients relapse after initial multimodal therapy. Until early 2000, the median …
[HTML][HTML] Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
A Argiris, AP Kotsakis, T Hoang, FP Worden… - Annals of oncology, 2013 - Elsevier
Background We evaluated combined targeting with cetuximab, an anti-epidermal growth
factor receptor (EGFR) monoclonal antibody, and bevacizumab, an anti-vascular endothelial …
factor receptor (EGFR) monoclonal antibody, and bevacizumab, an anti-vascular endothelial …
[HTML][HTML] A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma …
Background An open-label, multicenter, single-arm phase II trial was conducted to
investigate the clinical activity of dacomitinib in recurrent/metastatic squamous-cell …
investigate the clinical activity of dacomitinib in recurrent/metastatic squamous-cell …
Clinical determinants of weight loss in patients receiving radiation and chemoirradiation for head and neck cancer: a prospective longitudinal view
C Kubrak, K Olson, N Jha, R Scrimger… - Head & …, 2013 - Wiley Online Library
Background We aimed to determine the effects of systemic inflammation and symptoms of
head and neck cancer patients on dietary intake and weight in relation to mode of treatment …
head and neck cancer patients on dietary intake and weight in relation to mode of treatment …
The head and neck symptom checklist©: an instrument to evaluate nutrition impact symptoms effect on energy intake and weight loss
C Kubrak, K Olson, VE Baracos - Supportive care in cancer, 2013 - Springer
Purpose This study aimed to validate the Head and Neck Patient Symptom
Checklist©(HNSC©) by tracing the prevalence and interference with eating of nutrition …
Checklist©(HNSC©) by tracing the prevalence and interference with eating of nutrition …
[HTML][HTML] Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck
JB Vermorken, L Licitra, J Stöhlmacher-Williams… - European Journal of …, 2013 - Elsevier
Purpose Platinum/5-fluorouracil plus cetuximab is a standard systemic treatment for
recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) …
recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) …